- Home
- ZLAB vs HCM Comparison
ZLAB vs HCM Comparison
Compare ZLAB & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- HCM
- Stock Information
- Founded
- ZLAB 2013
- HCM 2000
- Country
- ZLAB China
- HCM Hong Kong
- Employees
- ZLAB N/A
- HCM N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- HCM Health Care
- Exchange
- ZLAB Nasdaq
- HCM Nasdaq
- Market Cap
- ZLAB 3.2B
- HCM 2.6B
- IPO Year
- ZLAB 2017
- HCM N/A
- Fundamental
- Price
- ZLAB $26.35
- HCM $14.89
- Analyst Decision
- ZLAB Buy
- HCM Sell
- Analyst Count
- ZLAB 6
- HCM 1
- Target Price
- ZLAB $57.22
- HCM $13.75
- AVG Volume (30 Days)
- ZLAB 613.7K
- HCM 44.7K
- Earning Date
- ZLAB 11-06-2025
- HCM 08-07-2025
- Dividend Yield
- ZLAB N/A
- HCM N/A
- EPS Growth
- ZLAB N/A
- HCM N/A
- EPS
- ZLAB N/A
- HCM 0.53
- Revenue
- ZLAB $427,799,000.00
- HCM $602,197,000.00
- Revenue This Year
- ZLAB $41.80
- HCM N/A
- Revenue Next Year
- ZLAB $49.93
- HCM $15.49
- P/E Ratio
- ZLAB N/A
- HCM $5.56
- Revenue Growth
- ZLAB 32.56
- HCM N/A
- 52 Week Low
- ZLAB $23.82
- HCM $11.51
- 52 Week High
- ZLAB $44.34
- HCM $21.25
- Technical
- Relative Strength Index (RSI)
- ZLAB 30.35
- HCM 39.75
- Support Level
- ZLAB $26.07
- HCM $14.60
- Resistance Level
- ZLAB $29.77
- HCM $15.34
- Average True Range (ATR)
- ZLAB 1.21
- HCM 0.31
- MACD
- ZLAB -0.41
- HCM -0.06
- Stochastic Oscillator
- ZLAB 3.54
- HCM 15.83
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.